Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
21 Août 2023 - 1:30PM
Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage
biotechnology company advancing differentiated biologics for the
treatment of atopic dermatitis (AD), chronic obstructive pulmonary
disease and other inflammatory and immunology (I&I)
indications, today announced the appointment of Mark C. McKenna as
Chairman of its board of directors. Mr. McKenna’s knowledge and
successful track record in the I&I space as well as his
significant development, commercial and executive management
experience contributed to the Apogee board of directors’ selection
decision.
“We are thrilled to welcome Mark as chair of our board and to
expand our team with such an accomplished biopharma executive and
leader,” said Michael Henderson, M.D., Chief Executive Officer of
Apogee. “Mark has been at the helm of driving success and value
creation for multiple companies, and we look forward to tapping
into his extensive experience in corporate strategy, portfolio
development and commercialization as we chart a transformative path
forward. With Mark’s insights, we are further poised to propel
Apogee towards continued innovation and growth, solidifying our
commitment to advancing differentiated biologics for patients.”
Mr. McKenna is the former President, Chief Executive Officer and
Chairman of the board of directors of Prometheus Biosciences, Inc.,
which was acquired by Merck & Co., Inc. in June 2023 for
approximately $10.8 billion, representing the largest pre-Phase 3
biopharma acquisition to date. Prior to joining Prometheus, Mr.
McKenna was a corporate officer of Bausch Health and served as
President of the subsidiary Salix Pharmaceuticals, where he
revitalized Bausch’s gastroenterology business with a series of
strategic acquisitions and product launches, doubling revenue to
exceed $2 billion while enhancing operating margins. Prior to
Salix, Mr. McKenna spent more than a decade in various roles with
Bausch + Lomb, also a division of Bausch, most recently as Senior
Vice President and General Manager of its U.S. Vision Care
business. Mr. McKenna was Ernst & Young Entrepreneur of the
Year in 2023 and holds a B.S. in marketing from Arizona State
University and an MBA from Azusa Pacific University.
“I am honored to join the Apogee team, particularly at this
exciting time in the company’s evolution,” said Mr. McKenna. “I
look forward to leveraging my experience to contribute to the
company’s strategy of targeting clinically validated mechanisms
with antibodies that have been optimized to be potentially
best-in-class therapeutics, advancement of its pipeline and
establishment of a clear path to commercialization. Apogee has
great potential to disrupt the immunology space, and with its
strong financial position from its successful upsized IPO and its
talented team and notable directors, I am confident we can
transform the lives of patients living with I&I diseases.”
“On behalf of the entire Apogee Board, I want to extend a warm
welcome to Mark as the new Chairman,” said Peter Harwin, Managing
Member at Fairmount Funds Management and member of Apogee’s board
of directors. “Mark’s track record of value creation, corporate
leadership and product development is exceptional, making him a
valuable addition to our team. His strategic insights and wealth of
experience in guiding companies through all stages will undoubtedly
enhance Apogee’s efforts to deliver transformative biologics for
patients.”
About Apogee Therapeutics
Apogee Therapeutics, Inc. (Nasdaq: APGE) is a clinical-stage
biotechnology company seeking to develop differentiated biologics
for the treatment of atopic dermatitis (AD), chronic obstructive
pulmonary disease (COPD) and other inflammatory and immunology
indications with high unmet need. Apogee’s antibody programs are
designed to overcome limitations of existing therapies by targeting
well-established mechanisms of action and incorporating advanced
antibody engineering to optimize half-life and other properties.
The Company’s two most advanced programs are APG777 and APG808,
which are being initially developed for the treatment of AD and
COPD, respectively. Based on a broad pipeline and depth of
expertise, the Company believes it can deliver value and meaningful
benefit to patients underserved by today’s standard of care. For
more information, please visit www.apogeetherapeutics.com.
Investor
Contacts:
Noel KurdiVP of Investor RelationsApogee
Therapeuticsnoel.kurdi@apogeetherapeutics.com
Alex StrausTHRUST Strategic Communicationsalex@thrustsc.com
Media Contact:
Dan Budwick1AB Mediadan@1abmedia.com
Apogee Therapeutics (NASDAQ:APGE)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Apogee Therapeutics (NASDAQ:APGE)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024